Mirabegron vs. solifenacin in control of endoscopically inserted ureteral stent-related symptoms.
DJ-stent
Lower urinary tract symptoms
Mirabegron
Solifenacin
Journal
World journal of urology
ISSN: 1433-8726
Titre abrégé: World J Urol
Pays: Germany
ID NLM: 8307716
Informations de publication
Date de publication:
Aug 2022
Aug 2022
Historique:
received:
13
01
2022
accepted:
01
06
2022
pubmed:
28
6
2022
medline:
16
7
2022
entrez:
27
6
2022
Statut:
ppublish
Résumé
We aimed to assess the efficacy and safety of Mirabegron vs. solifenacin to treat LUTS resulting from DJ-stent insertion. A total of 97 patients who had DJ-stent inserted for urinary stone disease were randomly divided into three groups according to received treatment. Group A took Mirabegron 50 mg daily, group B took solifenacin 5 mg daily from the 4th day after stent placement until the stent was removed, and group C only was hydrated well. All patients were evaluated by USSQ and IPSS at 4th day post-insertion of ureteral stent, follow-up day before removing of stent and post-removal of stent. The USSQ urinary symptom scores at day 4 comparing to day of removal of stent showed significant difference in between study groups (32 ± 6-13 ± 6 vs. 31 ± 6-14 ± 4 in Mirabegron and solifenacin, respectively) and without significant difference in control group. The USSQ body pain score significantly decreased in both Mirabegron and solifenacin groups at day of stent removal comparing to day 4 post-insertion of DJ with insignificant decreasing in the control group. Quality of life scores showed significant improving in Mirabegron and solifenacin group, and there was no difference in control group at 4 and 14 days after treatment. No severe complications were observed in either group. In our series, we indicate that Mirabegron and solifenacin can be used to improve symptoms caused by the insertion of DJ-stent without significant difference.
Identifiants
pubmed: 35760910
doi: 10.1007/s00345-022-04068-2
pii: 10.1007/s00345-022-04068-2
doi:
Substances chimiques
Acetanilides
0
Thiazoles
0
Urological Agents
0
Solifenacin Succinate
KKA5DLD701
mirabegron
MVR3JL3B2V
Types de publication
Journal Article
Randomized Controlled Trial
Langues
eng
Sous-ensembles de citation
IM
Pagination
2113-2119Informations de copyright
© 2022. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.
Références
Chew BH, Knudsen BE, Denstedt JD (2004) The use of stents in contemporary urology. Curr Opin Urol 14(2):111–115
doi: 10.1097/00042307-200403000-00011
Joshi HB, Stainthorpe A, MacDonagh RP, Keeley FX Jr, Timoney AG, Barry MJ (2003) Indwelling ureteral stents: evaluation of symptoms, quality of life and utility. J Urol 169:1065–1069
doi: 10.1097/01.ju.0000048980.33855.90
Damiano R, Autorino R, De Sio M, Cantiello F, Quarto G, Perdona S et al (2005) Does the ureteral stents impact urinary symptoms and quality of life? A prospective randomized study. J Eur Urol 48:673–678
doi: 10.1016/j.eururo.2005.06.006
Lim SJ, Sul KC, Song HK, Na GY, Shin HJ, Oh HT et al (2010) Chages in urinary symptoms and tolerance due to long-term ureteral double-J stenting. Int Neuroural J 14:93–99
doi: 10.5213/inj.2010.14.2.93
Leibovici D, Cooper A, Lindner A, Otrowsky R, Kleinmann J, Velikanov S et al (2005) Ureteral stents: Morbidity and impact on quality of life. Isr Med Assoc J 7:491–494
pubmed: 16106772
Hughes B, Wiseman OJ, Thompson T, Masood J, Daron RS, Mcllhenny C et al (2014) The dilemma of post-ureteroscopy stenting. BJU Int 113:184–185
doi: 10.1111/bju.12482
Joshi HB, Newns N, Stainthorpe A, MacDonagh RP, Keeley AG, Timoney AG (2003) Ureteral stent symptom questionnaire. Development and validation of a multidimensional quality of life measure. J Urol 169:1060–1064
doi: 10.1097/01.ju.0000049198.53424.1d
El-Nahas AR, Tharwat M, Elsaadany M, Mosbah A, Metwally MA, Hawary A et al (2014) Validation of the Arabic linguistic version of the ureteral stent symptoms questionnaire. Arab J Urol 12:290–293
doi: 10.1016/j.aju.2014.08.001
Kuyumcuoglu U, Eryildirim B, Tuncer M, Faydaci G, Tarhan F, Ozgul A (2012) Effectiveness of medical treatment in overcoming the ureteral double-J stent related symptoms. Can Urol Assoc J 6:234–237
doi: 10.5489/cuaj.145
Pricop C, Ciuta C, Mischianu D, Rusu F (2009) Is there a role for tamsulosin or solifenacine in the management of urinary tract symptoms in patients with double-J stent? J Urol 74:S25
doi: 10.1016/j.urology.2009.07.1132
Zhou L, Cai X, Li H, Wang KJ (2015) Effects of α-blockers, antimuscarinics, or combination therapy in relieving ureteral stent-related symptoms: a meta-analysis. J Endourol 29(6):650–656
doi: 10.1089/end.2014.0715
Aytac S, Caglar Y, Ozgur H, Ahmet U (2020) Treatment of ureteral catheter related symptoms; mirabegron versus tamsulosin/solifenacin combination: a randomized controlled trial. Arch Esp Urol 73(1):54–59
Kelleher C, Hakimi Z, Zur R, Siddiqui E, Maman K, Aballéa S et al (2018) Efficacy and tolerability of mirabegron compared with antimuscarinic monotherapy or combination therapies for overactive bladder: a systematic review and network meta-analysis. Eur Urol 74(3):324–333
doi: 10.1016/j.eururo.2018.03.020
Tae BS, Cho S, Jeon BJ, Choi H, Park JY, Cho SY et al (2018) Does mirabegron relieve ureteric stent-related discomfort? A prospective, randomized, multicentre study. BJU Int 122(5):866–872
doi: 10.1111/bju.14416
Chapple CR, Siddiqui E (2017) Mirabegron for the treatment of overactive bladder: a review of efficacy, safety and tolerability with a focus on male, elderly and antimuscarinic poorresponder populations, and patients with OAB in Asia. Expert Rev Clin Pharmacol 10:131–151
doi: 10.1080/17512433.2017.1275570
Chen HL, Chen TC, Chang HM, Juan YS, Huang WH, Pan HF et al (2018) Mirabegron is alternative to antimuscarinic agents for overactive bladder without higher risk in hypertension: a systematic review and meta-analysis. World J Urol 36(8):1285–1297
doi: 10.1007/s00345-018-2268-9